BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sieber MA, Lengsfeld P, Frenzel T, Golfier S, Schmitt-Willich H, Siegmund F, Walter J, Weinmann HJ, Pietsch H. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 2008;18:2164-73. [PMID: 18545998 DOI: 10.1007/s00330-008-0977-y] [Cited by in Crossref: 153] [Cited by in F6Publishing: 134] [Article Influence: 11.8] [Reference Citation Analysis]
Number Citing Articles
1 Pietsch H, Lengsfeld P, Jost G, Frenzel T, Hütter J, Sieber MA. Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents. Eur Radiol 2009;19:1417-24. [PMID: 19169690 DOI: 10.1007/s00330-008-1259-4] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 4.3] [Reference Citation Analysis]
2 Kanakia S, Toussaint J, Kukarni P, Lee S, Chowdhury SM, Khan S, Mallipattu SK, Shroyer KR, Moore W, Sitharaman B. Safety and Efficacy of A High Performance Graphene-Based Magnetic Resonance Imaging Contrast Agent for Renal Abnormalities. Graphene Technol 2016;1:17-28. [PMID: 28261636 DOI: 10.1007/s41127-016-0001-2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Fretellier N, Granottier A, Rasschaert M, Grindel AL, Baudimont F, Robert P, Idée JM, Corot C. Does Age Interfere With Gadolinium Toxicity and Presence in Brain and Bone Tissues?: A Comparative Gadoterate Versus Gadodiamide Study in Juvenile and Adult Rats. Invest Radiol 2019;54:61-71. [PMID: 30394964 DOI: 10.1097/RLI.0000000000000517] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
4 Ponrartana S, Moore MM, Chan SS, Victoria T, Dillman JR, Chavhan GB. Safety issues related to intravenous contrast agent use in magnetic resonance imaging. Pediatr Radiol 2021;51:736-47. [PMID: 33871726 DOI: 10.1007/s00247-020-04896-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Pietsch H, Lengsfeld P, Steger-Hartmann T, Löwe A, Frenzel T, Hütter J, Sieber MA. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol 2009;44:226-33. [PMID: 19252439 DOI: 10.1097/RLI.0b013e3181998eb7] [Cited by in Crossref: 68] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
6 Kong Y, Zhang S, Wang J, Han C, Yu N, Liu Q, Wang W, Xu K. Potential toxicity evaluation and comparison within multiple mice organs after repeat injections of linear versus macrocyclic gadolinium-based contrast agents: A comprehensive and time course study. Toxicol Lett 2021;350:152-61. [PMID: 34311048 DOI: 10.1016/j.toxlet.2021.07.016] [Reference Citation Analysis]
7 Wack C, Steger-Hartmann T, Mylecraine L, Hofmeister R. Toxicological safety evaluation of gadobutrol. Invest Radiol 2012;47:611-23. [PMID: 23011188 DOI: 10.1097/RLI.0b013e318263f128] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
8 Pietsch H, Jost G, Frenzel T, Raschke M, Walter J, Schirmer H, Hütter J, Sieber MA. Efficacy and safety of lanthanoids as X-ray contrast agents. European Journal of Radiology 2011;80:349-56. [DOI: 10.1016/j.ejrad.2009.10.023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
9 Hadizadeh DR, Jost G, Pietsch H, Weibrecht M, Perkuhn M, Boschewitz JM, Keil VC, Träber F, Kukuk GM, Schild HH, Willinek WA. Intraindividual quantitative and qualitative comparison of gadopentetate dimeglumine and gadobutrol in time-resolved contrast-enhanced 4-dimensional magnetic resonance angiography in minipigs. Invest Radiol 2014;49:457-64. [PMID: 24598442 DOI: 10.1097/RLI.0000000000000036] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
10 Bernstein EJ, Schmidt-lauber C, Kay J. Nephrogenic systemic fibrosis: A systemic fibrosing disease resulting from gadolinium exposure. Best Practice & Research Clinical Rheumatology 2012;26:489-503. [DOI: 10.1016/j.berh.2012.07.008] [Cited by in Crossref: 61] [Cited by in F6Publishing: 44] [Article Influence: 6.8] [Reference Citation Analysis]
11 Langer RD, Lorke DE, Neidl van Gorkom KF, Petroianu G, Azimullah S, Nurulain SM, Singh S, Fuchsjäger M. In an animal model nephrogenic systemic fibrosis cannot be induced by intraperitoneal injection of high-dose gadolinium based contrast agents. Eur J Radiol 2012;81:2562-7. [PMID: 22304979 DOI: 10.1016/j.ejrad.2011.10.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
12 Ye Z, Zhou Z, Ayat N, Wu X, Jin E, Shi X, Lu ZR. A neutral polydisulfide containing Gd(III) DOTA monoamide as a redox-sensitive biodegradable macromolecular MRI contrast agent. Contrast Media Mol Imaging 2016;11:32-40. [PMID: 26218648 DOI: 10.1002/cmmi.1655] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
13 Yon M, Billotey C, Marty J. Gadolinium-based contrast agents: From gadolinium complexes to colloidal systems. International Journal of Pharmaceutics 2019;569:118577. [DOI: 10.1016/j.ijpharm.2019.118577] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
14 Kramer H, Runge VM, Naul LG, Loynachan AT, Reiser MF, Wintersperger BJ. Brain MRI With Single-Dose (0.1 mmol/kg) Gadobutrol at 1.5 T and 3 T: Comparison With 0.15 mmol/kg Gadoterate Meglumine. American Journal of Roentgenology 2010;194:1337-42. [DOI: 10.2214/ajr.09.3427] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Sadowski EA, Djamali A, Wentland AL, Muehrer R, Becker BN, Grist TM, Fain SB. Blood oxygen level-dependent and perfusion magnetic resonance imaging: detecting differences in oxygen bioavailability and blood flow in transplanted kidneys. Magn Reson Imaging. 2010;28:56-64. [PMID: 19577402 DOI: 10.1016/j.mri.2009.05.044] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 4.8] [Reference Citation Analysis]
16 Renz DM, Durmus T, Böttcher J, Taupitz M, Diekmann F, Huppertz A, Pfeil A, Maurer MH, Streitparth F, Bick U, Hamm B, Fallenberg EM. Comparison of Gadoteric Acid and Gadobutrol for Detection as Well as Morphologic and Dynamic Characterization of Lesions on Breast Dynamic Contrast-Enhanced Magnetic Resonance Imaging: . Investigative Radiology 2014;49:474-84. [DOI: 10.1097/rli.0000000000000039] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 2.1] [Reference Citation Analysis]
17 Dillman JR, Davenport MS. Gadolinium retention - 5 years later…. Pediatr Radiol 2020;50:166-7. [PMID: 31975183 DOI: 10.1007/s00247-019-04540-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Jansen SA, Paunesku T, Fan X, Woloschak GE, Vogt S, Conzen SD, Krausz T, Newstead GM, Karczmar GS. Ductal carcinoma in situ: X-ray fluorescence microscopy and dynamic contrast-enhanced MR imaging reveals gadolinium uptake within neoplastic mammary ducts in a murine model. Radiology 2009;253:399-406. [PMID: 19864527 DOI: 10.1148/radiol.2533082026] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 5.3] [Reference Citation Analysis]
19 Stojanov DA, Aracki-trenkic A, Vojinovic S, Benedeto-stojanov D, Ljubisavljevic S. Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol 2016;26:807-15. [DOI: 10.1007/s00330-015-3879-9] [Cited by in Crossref: 151] [Cited by in F6Publishing: 141] [Article Influence: 25.2] [Reference Citation Analysis]
20 Costa AF, van der Pol CB, Maralani PJ, Mcinnes MD, Shewchuk JR, Verma R, Hurrell C, Schieda N. Gadolinium Deposition in the Brain: A Systematic Review of Existing Guidelines and Policy Statement Issued by the Canadian Association of Radiologists. Can Assoc Radiol J 2018;69:373-82. [DOI: 10.1016/j.carj.2018.04.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 10.3] [Reference Citation Analysis]
21 Perazella MA. Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephrol. 2009;4:461-469. [PMID: 19201920 DOI: 10.2215/cjn.06011108] [Cited by in Crossref: 178] [Cited by in F6Publishing: 69] [Article Influence: 14.8] [Reference Citation Analysis]
22 Ramalho M, Ramalho J, Burke LM, Semelka RC. Gadolinium Retention and Toxicity—An Update. Advances in Chronic Kidney Disease 2017;24:138-46. [DOI: 10.1053/j.ackd.2017.03.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 13.0] [Reference Citation Analysis]
23 Bruce R, Wentland AL, Haemel AK, Garrett RW, Sadowski DR, Djamali A, Sadowski EA. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide. Invest Radiol. 2016;51:701-705. [PMID: 26885631 DOI: 10.1097/rli.0000000000000259] [Cited by in Crossref: 34] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
24 Wáng YX, Schroeder J, Siegmund H, Idée JM, Fretellier N, Jestin-Mayer G, Factor C, Deng M, Kang W, Morcos SK. Total gadolinium tissue deposition and skin structural findings following the administration of structurally different gadolinium chelates in healthy and ovariectomized female rats. Quant Imaging Med Surg 2015;5:534-45. [PMID: 26435917 DOI: 10.3978/j.issn.2223-4292.2015.05.03] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
25 Wallnöfer EA, Thurner GC, Kremser C, Talasz H, Stollenwerk MM, Helbok A, Klammsteiner N, Albrecht-Schgoer K, Dietrich H, Jaschke W, Debbage P. Albumin-based nanoparticles as contrast medium for MRI: vascular imaging, tissue and cell interactions, and pharmacokinetics of second-generation nanoparticles. Histochem Cell Biol 2021;155:19-73. [PMID: 33040183 DOI: 10.1007/s00418-020-01919-0] [Reference Citation Analysis]
26 Idée J, Fretellier N, Robic C, Corot C. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update. Critical Reviews in Toxicology 2014;44:895-913. [DOI: 10.3109/10408444.2014.955568] [Cited by in Crossref: 66] [Cited by in F6Publishing: 46] [Article Influence: 9.4] [Reference Citation Analysis]
27 Abujudeh HH, Kaewlai R, Kagan A, Chibnik LB, Nazarian RM, High WA, Kay J. Nephrogenic Systemic Fibrosis after Gadopentetate Dimeglumine Exposure: Case Series of 36 Patients. Radiology 2009;253:81-9. [DOI: 10.1148/radiol.2531082160] [Cited by in Crossref: 76] [Cited by in F6Publishing: 65] [Article Influence: 6.3] [Reference Citation Analysis]
28 Morcos SK. Gadolinium Chelates and Stability. In: Thomsen HS, Webb JAW, editors. Contrast Media. Berlin: Springer Berlin Heidelberg; 2014. pp. 175-80. [DOI: 10.1007/174_2013_895] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Morcos SK. Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far? Eur Radiol 2011;21:496-500. [DOI: 10.1007/s00330-010-1951-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
30 Rudnick MR, Wahba IM, Leonberg-Yoo AK, Miskulin D, Litt HI. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review. Am J Kidney Dis 2021;77:517-28. [PMID: 32861792 DOI: 10.1053/j.ajkd.2020.07.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
31 Hellman RN. Gadolinium-induced nephrogenic systemic fibrosis. Semin Nephrol 2011;31:310-6. [PMID: 21784280 DOI: 10.1016/j.semnephrol.2011.05.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
32 Erdoğan MA, Apaydin M, Armagan G, Taskiran D. Evaluation of toxicity of gadolinium-based contrast agents on neuronal cells. Acta Radiol 2021;62:206-14. [PMID: 32366109 DOI: 10.1177/0284185120920801] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Garcia J, Liu SZ, Louie AY. Biological effects of MRI contrast agents: gadolinium retention, potential mechanisms and a role for phosphorus. Philos Trans A Math Phys Eng Sci 2017;375:20170180. [PMID: 29038383 DOI: 10.1098/rsta.2017.0180] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
34 Pietsch H, Raschke M, Ellinger-ziegelbauer H, Jost G, Walter J, Frenzel T, Lenhard D, Hütter J, Sieber MA. The Role of Residual Gadolinium in the Induction of Nephrogenic Systemic Fibrosis-Like Skin Lesions in Rats: . Investigative Radiology 2011;46:48-56. [DOI: 10.1097/rli.0b013e3181efd49a] [Cited by in Crossref: 35] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
35 Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, Abujudeh HH. Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology 2011;260:105-11. [PMID: 21586680 DOI: 10.1148/radiol.11102340] [Cited by in Crossref: 113] [Cited by in F6Publishing: 87] [Article Influence: 11.3] [Reference Citation Analysis]
36 Frenzel T, Apte C, Jost G, Schöckel L, Lohrke J, Pietsch H. Quantification and Assessment of the Chemical Form of Residual Gadolinium in the Brain After Repeated Administration of Gadolinium-Based Contrast Agents: Comparative Study in Rats. Invest Radiol 2017;52:396-404. [PMID: 28125438 DOI: 10.1097/RLI.0000000000000352] [Cited by in Crossref: 141] [Cited by in F6Publishing: 48] [Article Influence: 47.0] [Reference Citation Analysis]
37 Adin ME, Kleinberg L, Vaidya D, Zan E, Mirbagheri S, Yousem DM. Hyperintense Dentate Nuclei on T1-Weighted MRI: Relation to Repeat Gadolinium Administration. AJNR Am J Neuroradiol 2015;36:1859-65. [PMID: 26294649 DOI: 10.3174/ajnr.A4378] [Cited by in Crossref: 104] [Cited by in F6Publishing: 43] [Article Influence: 17.3] [Reference Citation Analysis]
38 Abdel-Kader K, Patel PR, Kallen AJ, Sinkowitz-Cochran RL, Bolton WK, Unruh ML. Nephrogenic systemic fibrosis: a survey of nephrologists' perceptions and practices. Clin J Am Soc Nephrol 2010;5:964-71. [PMID: 20299369 DOI: 10.2215/CJN.00140110] [Cited by in Crossref: 7] [Article Influence: 0.6] [Reference Citation Analysis]
39 Morelli JN, Gerdes CM, Zhang W, Williams JM, Saettele MR, Ai F. Enhancement in a brain glioma model: A comparison of half-dose gadobenate dimeglumine versus full-dose gadopentetate dimeglumine at 1.5 and 3 T: Half-Dose Gadobenate Dimeglumine Brain Imaging. J Magn Reson Imaging 2013;38:306-11. [DOI: 10.1002/jmri.23965] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
40 Zhu W, Artemov D. Biocompatible blood pool MRI contrast agents based on hyaluronan. Contrast Media Mol Imaging 2011;6:61-8. [PMID: 21504061 DOI: 10.1002/cmmi.404] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
41 Kanda T, Fukusato T, Matsuda M, Toyoda K, Oba H, Kotoku J, Haruyama T, Kitajima K, Furui S. Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy. Radiology 2015;276:228-32. [DOI: 10.1148/radiol.2015142690] [Cited by in Crossref: 541] [Cited by in F6Publishing: 460] [Article Influence: 90.2] [Reference Citation Analysis]
42 Wu X, Zong Y, Ye Z, Lu ZR. Stability and biodistribution of a biodegradable macromolecular MRI contrast agent Gd-DTPA cystamine copolymers (GDCC) in rats. Pharm Res 2010;27:1390-7. [PMID: 20393871 DOI: 10.1007/s11095-010-0131-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
43 Semelka RC, Ramalho M, Jay M, Hickey L, Hickey J. Intravenous Calcium-/Zinc-Diethylene Triamine Penta-Acetic Acid in Patients With Presumed Gadolinium Deposition Disease: A Preliminary Report on 25 Patients. Invest Radiol 2018;53:373-9. [PMID: 29419708 DOI: 10.1097/RLI.0000000000000453] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 8.5] [Reference Citation Analysis]
44 Fretellier N, Salhi M, Schroeder J, Siegmund H, Chevalier T, Bruneval P, Jestin-Mayer G, Delaloge F, Factor C, Mayer JF, Fabicki JM, Robic C, Bonnemain B, Idée JM, Corot C. Distribution profile of gadolinium in gadolinium chelate-treated renally-impaired rats: role of pharmaceutical formulation. Eur J Pharm Sci 2015;72:46-56. [PMID: 25736527 DOI: 10.1016/j.ejps.2015.02.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
45 Mckinney AM, Gawande R, Pezeshk P, Truwit CL, Rykken JB. Preliminary experience with intravenous gadoxetate disodium as a craniospinal MR contrast agent. European Journal of Radiology 2015;84:2539-47. [DOI: 10.1016/j.ejrad.2015.09.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
46 Braun K, Dunsch L, Pipkorn R, Bock M, Baeuerle T, Yang S, Waldeck W, Wiessler M. Gain of a 500-fold sensitivity on an intravital MR contrast agent based on an endohedral gadolinium-cluster-fullerene-conjugate: a new chance in cancer diagnostics. Int J Med Sci 2010;7:136-46. [PMID: 20567614 DOI: 10.7150/ijms.7.136] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
47 Fretellier N, Maazouz M, Luseau A, Baudimont F, Jestin-mayer G, Bourgery S, Rasschaert M, Bruneval P, Factor C, Mecieb F, Idée J, Corot C. Safety profiles of gadolinium chelates in juvenile rats differ according to the risk of dissociation. Reproductive Toxicology 2014;50:171-9. [DOI: 10.1016/j.reprotox.2014.10.024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
48 Semelka RC, Commander CW, Jay M, Burke LM, Ramalho M. Presumed Gadolinium Toxicity in Subjects With Normal Renal Function: A Report of 4 Cases. Invest Radiol 2016;51:661-5. [DOI: 10.1097/rli.0000000000000318] [Cited by in Crossref: 52] [Cited by in F6Publishing: 16] [Article Influence: 10.4] [Reference Citation Analysis]
49 Lohrke J, Frisk AL, Frenzel T, Schöckel L, Rosenbruch M, Jost G, Lenhard DC, Sieber MA, Nischwitz V, Küppers A, Pietsch H. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents. Invest Radiol 2017;52:324-33. [PMID: 28323657 DOI: 10.1097/RLI.0000000000000344] [Cited by in Crossref: 105] [Cited by in F6Publishing: 44] [Article Influence: 35.0] [Reference Citation Analysis]
50 Hope TA, High WA, Leboit PE, Chaopathomkul B, Rogut VS, Herfkens RJ, Brasch RC. Nephrogenic Systemic Fibrosis in Rats Treated with Erythropoietin and Intravenous Iron. Radiology 2009;253:390-8. [DOI: 10.1148/radiol.2532090580] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
51 Thomsen HS, Morcos SK, Almén T, Bellin MF, Bertolotto M, Bongartz G, Clement O, Leander P, Heinz-Peer G, Reimer P. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2013;23:307-318. [PMID: 22865271 DOI: 10.1007/s00330-012-2597-9] [Cited by in Crossref: 305] [Cited by in F6Publishing: 235] [Article Influence: 33.9] [Reference Citation Analysis]
52 Bardin T, Richette P. Rheumatic manifestations of renal disease. Current Opinion in Rheumatology 2009;21:55-61. [DOI: 10.1097/bor.0b013e32831ca5c5] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
53 Huckle JE, Altun E, Jay M, Semelka RC. Gadolinium Deposition in Humans: When Did We Learn That Gadolinium Was Deposited In Vivo? Invest Radiol. 2016;51:236-240. [PMID: 26588463 DOI: 10.1097/rli.0000000000000228] [Cited by in Crossref: 38] [Cited by in F6Publishing: 8] [Article Influence: 7.6] [Reference Citation Analysis]
54 Prybylski JP, Jay M. The Impact of Excess Ligand on the Retention of Nonionic, Linear Gadolinium-Based Contrast Agents in Patients With Various Levels of Renal Dysfunction: A Review and Simulation Analysis. Adv Chronic Kidney Dis 2017;24:176-82. [PMID: 28501081 DOI: 10.1053/j.ackd.2017.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
55 Anzalone N. Comparative studies of different gadolinium agents in brain tumors: differences between gadolinium chelates and their possible influence on imaging features. AJNR Am J Neuroradiol 2010;31:981-2. [PMID: 20299432 DOI: 10.3174/ajnr.A2068] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
56 Igreja ACDSM, Mesquita KDC, Cowper SE, Costa IMC. Nephrogenic systemic fibrosis: concepts and perspectives. An Bras Dermatol 2012;87:597-607. [DOI: 10.1590/s0365-05962012000400013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
57 Prybylski JP, Coste Sanchez C, Jay M. Impact of chelation timing on gadolinium deposition in rats after contrast administration. Magn Reson Imaging 2019;55:140-4. [PMID: 30321663 DOI: 10.1016/j.mri.2018.10.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
58 Pietsch H, Pering C, Lengsfeld P, Walter J, Steger-hartmann T, Golfier S, Frenzel T, Hütter J, Weinmann H, Sieber MA. Evaluating the role of zinc in the occurrence of fibrosis of the skin: A preclinical study. J Magn Reson Imaging 2009;30:374-83. [DOI: 10.1002/jmri.21845] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
59 Zhang G, Zhang R, Melancon MP, Wong K, You J, Huang Q, Bankson J, Liang D, Li C. The degradation and clearance of Poly(N-hydroxypropyl-L-glutamine)-DTPA-Gd as a blood pool MRI contrast agent. Biomaterials 2012;33:5376-83. [PMID: 22541356 DOI: 10.1016/j.biomaterials.2012.03.081] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
60 Martí-bonmatí L, Martí-bonmatí E. Retención de compuestos de gadolinio usados en resonancia magnética: revisión crítica y recomendaciones de las agencias regulatorias. Radiología 2017;59:469-77. [DOI: 10.1016/j.rx.2017.09.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
61 Stanescu AL, Shaw DW, Murata N, Murata K, Rutledge JC, Maloney E, Maravilla KR. Brain tissue gadolinium retention in pediatric patients after contrast-enhanced magnetic resonance exams: pathological confirmation. Pediatr Radiol 2020;50:388-96. [DOI: 10.1007/s00247-019-04535-w] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 23.0] [Reference Citation Analysis]
62 Polasek M, Caravan P. Is macrocycle a synonym for kinetic inertness in Gd(III) Complexes? Effect of coordinating and noncoordinating substituents on inertness and relaxivity of Gd(III) chelates with DO3A-like ligands. Inorg Chem 2013;52:4084-96. [PMID: 23517079 DOI: 10.1021/ic400227k] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
63 Kindberg GM, Uran S, Friisk G, Martinsen I, Skotland T. The fate of Gd and chelate following intravenous injection of gadodiamide in rats. Eur Radiol 2010;20:1636-43. [PMID: 20157815 DOI: 10.1007/s00330-010-1716-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
64 Sieber MA, Steger-hartmann T, Lengsfeld P, Pietsch H. Gadolinium-based contrast agents and NSF: Evidence from animal experience. J Magn Reson Imaging 2009;30:1268-76. [DOI: 10.1002/jmri.21971] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 6.1] [Reference Citation Analysis]
65 Wadas TJ, Sherman CD, Miner JH, Duncan JR, Anderson CJ. The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice. Magn Reson Med 2010;64:1274-80. [PMID: 20648683 DOI: 10.1002/mrm.22553] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
66 Wahsner J, Gale EM, Rodríguez-Rodríguez A, Caravan P. Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers. Chem Rev 2019;119:957-1057. [PMID: 30350585 DOI: 10.1021/acs.chemrev.8b00363] [Cited by in Crossref: 389] [Cited by in F6Publishing: 302] [Article Influence: 129.7] [Reference Citation Analysis]
67 Kanda T, Osawa M, Oba H, Toyoda K, Kotoku J, Haruyama T, Takeshita K, Furui S. High Signal Intensity in Dentate Nucleus on Unenhanced T1-weighted MR Images: Association with Linear versus Macrocyclic Gadolinium Chelate Administration. Radiology. 2015;275:803-809. [PMID: 25633504 DOI: 10.1148/radiol.14140364] [Cited by in Crossref: 333] [Cited by in F6Publishing: 299] [Article Influence: 55.5] [Reference Citation Analysis]
68 Weller A, Barber JL, Olsen ØE. Gadolinium and nephrogenic systemic fibrosis: an update. Pediatr Nephrol 2014;29:1927-37. [DOI: 10.1007/s00467-013-2636-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
69 Webb JA, Thomsen HS. Gadolinium contrast media during pregnancy and lactation. Acta Radiol 2013;54:599-600. [PMID: 23966544 DOI: 10.1177/0284185113484894] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 2.9] [Reference Citation Analysis]
70 Endrikat J, Anzalone N. Gadobutrol in India-A Comprehensive Review of Safety and Efficacy. Magn Reson Insights 2017;10:1178623X17730048. [PMID: 28932122 DOI: 10.1177/1178623X17730048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
71 Glutig K, Bhargava R, Hahn G, Hirsch W, Kunze C, Mentzel HJ, Schaefer JF, Willinek W, Palkowitsch P; GARDIAN study group. Safety of gadobutrol in more than 1,000 pediatric patients: subanalysis of the GARDIAN study, a global multicenter prospective non-interventional study. Pediatr Radiol 2016;46:1317-23. [PMID: 27041276 DOI: 10.1007/s00247-016-3599-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
72 Haemel AK, Sadowski EA, Shafer MM, Djamali A. Update on nephrogenic systemic fibrosis: are we making progress?: Update on nephrogenic systemic fibrosis. International Journal of Dermatology 2011;50:659-66. [DOI: 10.1111/j.1365-4632.2010.04851.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
73 Clases D, Sperling M, Karst U. Analysis of metal-based contrast agents in medicine and the environment. TrAC Trends in Analytical Chemistry 2018;104:135-47. [DOI: 10.1016/j.trac.2017.12.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
74 Chehabeddine L, Al Saleh T, Baalbaki M, Saleh E, Khoury SJ, Hannoun S. Cumulative administrations of gadolinium-based contrast agents: risks of accumulation and toxicity of linear vs macrocyclic agents. Critical Reviews in Toxicology 2019;49:262-79. [DOI: 10.1080/10408444.2019.1592109] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
75 Riser BL, Barnes JL, Varani J. Balanced regulation of the CCN family of matricellular proteins: a novel approach to the prevention and treatment of fibrosis and cancer. J Cell Commun Signal 2015;9:327-39. [PMID: 26698861 DOI: 10.1007/s12079-015-0309-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
76 Ramalho J, Ramalho M, Semelka RC. Gadolinium Deposition and Toxicity: A Global Concern. Curr Radiol Rep 2016;4. [DOI: 10.1007/s40134-016-0187-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
77 Wagner B, Drel V, Gorin Y. Pathophysiology of gadolinium-associated systemic fibrosis. Am J Physiol Renal Physiol 2016;311:F1-F11. [PMID: 27147669 DOI: 10.1152/ajprenal.00166.2016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
78 DaSilva M, O'Brien Deming M, Fligiel SE, Dame MK, Johnson KJ, Swartz RD, Varani J. Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects. Invest Radiol 2010;45:733-9. [PMID: 20661146 DOI: 10.1097/RLI.0b013e3181e9436b] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
79 Anzalone N, Scarabino T, Venturi C, Cristaudo C, Tartaro A, Scotti G, Zimatore D, Floris R, Carriero A, Longo M, Cirillo M, Cova MA, Gatti S, Voth M, Colosimo C. Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting. Eur J Radiol 2013;82:139-45. [PMID: 21890295 DOI: 10.1016/j.ejrad.2011.07.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
80 Giorgi H, Ammerman J, Briffaux J, Fretellier N, Corot C, Bourrinet P. Non-clinical safety assessment of gadoterate meglumine (Dotarem®) in neonatal and juvenile rats. Regulatory Toxicology and Pharmacology 2015;73:960-70. [DOI: 10.1016/j.yrtph.2015.09.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
81 Choi JW, Moon WJ. Gadolinium Deposition in the Brain: Current Updates.Korean J Radiol. 2019;20:134-147. [PMID: 30627029 DOI: 10.3348/kjr.2018.0356] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 18.3] [Reference Citation Analysis]
82 Wentland AL, Sadowski EA, Djamali A, Grist TM, Becker BN, Fain SB. Quantitative MR measures of intrarenal perfusion in the assessment of transplanted kidneys: initial experience. Acad Radiol. 2009;16:1077-1085. [PMID: 19539502 DOI: 10.1016/j.acra.2009.03.020] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
83 Frenzel T, Lengsfeld P, Schirmer H, Hütter J, Weinmann HJ. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol 2008;43:817-28. [PMID: 19002053 DOI: 10.1097/RLI.0b013e3181852171] [Cited by in Crossref: 395] [Cited by in F6Publishing: 120] [Article Influence: 32.9] [Reference Citation Analysis]
84 Idée JM, Port M, Dencausse A, Lancelot E, Corot C. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin North Am 2009;47:855-69, vii. [PMID: 19744600 DOI: 10.1016/j.rcl.2009.06.006] [Cited by in Crossref: 65] [Cited by in F6Publishing: 53] [Article Influence: 5.4] [Reference Citation Analysis]
85 Essig M, Anzalone N, Combs SE, Dörfler À, Lee SK, Picozzi P, Rovira A, Weller M, Law M. MR imaging of neoplastic central nervous system lesions: review and recommendations for current practice. AJNR Am J Neuroradiol 2012;33:803-17. [PMID: 22016411 DOI: 10.3174/ajnr.A2640] [Cited by in Crossref: 66] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
86 Steger-Hartmann T, Raschke M, Riefke B, Pietsch H, Sieber MA, Walter J. The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis - a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide. Exp Toxicol Pathol 2009;61:537-52. [PMID: 19131226 DOI: 10.1016/j.etp.2008.11.004] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
87 Semelka RC, Ramalho J, Vakharia A, Alobaidy M, Burke LM, Jay M, Ramalho M. Gadolinium deposition disease: Initial description of a disease that has been around for a while. Magnetic Resonance Imaging 2016;34:1383-90. [DOI: 10.1016/j.mri.2016.07.016] [Cited by in Crossref: 82] [Cited by in F6Publishing: 70] [Article Influence: 16.4] [Reference Citation Analysis]
88 Haylor J, Schroeder J, Wagner B, Nutter F, Jestin G, Idée J, Morcos S. Skin Gadolinium Following Use of MR Contrast Agents in a Rat Model of Nephrogenic Systemic Fibrosis. Radiology 2012;263:107-16. [DOI: 10.1148/radiol.12110881] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
89 Kader A, Brangsch J, Kaufmann JO, Zhao J, Mangarova DB, Moeckel J, Adams LC, Sack I, Taupitz M, Hamm B, Makowski MR. Molecular MR Imaging of Prostate Cancer. Biomedicines 2020;9:1. [PMID: 33375045 DOI: 10.3390/biomedicines9010001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Bussi S, Coppo A, Botteron C, Fraimbault V, Fanizzi A, De Laurentiis E, Colombo Serra S, Kirchin MA, Tedoldi F, Maisano F. Differences in gadolinium retention after repeated injections of macrocyclic MR contrast agents to rats. J Magn Reson Imaging 2018;47:746-52. [PMID: 28730643 DOI: 10.1002/jmri.25822] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 17.0] [Reference Citation Analysis]
91 Tedeschi E, Caranci F, Giordano F, Angelini V, Cocozza S, Brunetti A. Gadolinium retention in the body: what we know and what we can do. Radiol med 2017;122:589-600. [DOI: 10.1007/s11547-017-0757-3] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 10.0] [Reference Citation Analysis]
92 Martin DR, Semelka RC, Chapman A, Peters H, Finn PJ, Kalb B, Thomsen H. Nephrogenic systemic fibrosis versus contrast-induced nephropathy: Risks and benefits of contrast-enhanced MR and CT in renally impaired patients. J Magn Reson Imaging 2009;30:1350-6. [DOI: 10.1002/jmri.21968] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
93 Scott LJ. Gadobutrol: A Review in Contrast-Enhanced MRI and MRA. Clin Drug Investig 2018;38:773-84. [PMID: 30006819 DOI: 10.1007/s40261-018-0674-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
94 Kanda T, Oba H, Toyoda K, Kitajima K, Furui S. Brain gadolinium deposition after administration of gadolinium-based contrast agents. Jpn J Radiol 2016;34:3-9. [DOI: 10.1007/s11604-015-0503-5] [Cited by in Crossref: 104] [Cited by in F6Publishing: 92] [Article Influence: 17.3] [Reference Citation Analysis]
95 Fretellier N, Idée J, Bruneval P, Guerret S, Daubiné F, Jestin G, Factor C, Poveda N, Dencausse A, Massicot F, Laprévote O, Mandet C, Bouzian N, Port M, Corot C. Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide. Br J Pharmacol 2012;165:1151-62. [PMID: 21740412 DOI: 10.1111/j.1476-5381.2011.01585.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
96 Lövblad KO, Anzalone N, Dörfler A, Essig M, Hurwitz B, Kappos L, Lee SK, Filippi M. MR imaging in multiple sclerosis: review and recommendations for current practice. AJNR Am J Neuroradiol 2010;31:983-9. [PMID: 20019103 DOI: 10.3174/ajnr.A1906] [Cited by in Crossref: 68] [Cited by in F6Publishing: 27] [Article Influence: 5.7] [Reference Citation Analysis]
97 Ebrahimi P, Barbieri M. Gadolinium as an Emerging Microcontaminant in Water Resources: Threats and Opportunities. Geosciences 2019;9:93. [DOI: 10.3390/geosciences9020093] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 13.5] [Reference Citation Analysis]
98 Delfino R, Biasotto M, Candido R, Altissimo M, Stebel M, Salomè M, van Elteren JT, Vogel Mikuš K, Zennaro C, Šala M, Addobbati R, Tromba G, Pascolo L. Gadolinium tissue deposition in the periodontal ligament of mice with reduced renal function exposed to Gd-based contrast agents. Toxicology Letters 2019;301:157-67. [DOI: 10.1016/j.toxlet.2018.11.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
99 Lledos M, Mirabello V, Sarpaki S, Ge H, Smugowski HJ, Carroll L, Aboagye EO, Aigbirhio FI, Botchway SW, Dilworth JR, Calatayud DG, Plucinski PK, Price GJ, Pascu SI. Synthesis, Radiolabelling and In Vitro Imaging of Multifunctional Nanoceramics. ChemNanoMat 2018;4:361-72. [PMID: 29938196 DOI: 10.1002/cnma.201700378] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
100 Perazella MA. Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm. Curr Opin Nephrol Hypertens 2009;18:519-25. [PMID: 19623065 DOI: 10.1097/MNH.0b013e3283309660] [Cited by in Crossref: 34] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
101 Bryant B, Im K, Broome D. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI. Clinical Radiology 2009;64:706-13. [DOI: 10.1016/j.crad.2009.04.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
102 Scott LJ. Gadobutrol: a review of its use for contrast-enhanced magnetic resonance imaging in adults and children. Clin Drug Investig 2013;33:303-14. [PMID: 23435930 DOI: 10.1007/s40261-013-0066-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
103 Fretellier N, Bouzian N, Parmentier N, Bruneval P, Jestin G, Factor C, Mandet C, Daubiné F, Massicot F, Laprévote O, Hollenbeck C, Port M, Idée J, Corot C. Nephrogenic Systemic Fibrosis-Like Effects of Magnetic Resonance Imaging Contrast Agents in Rats with Adenine-Induced Renal Failure. Toxicological Sciences 2013;131:259-70. [DOI: 10.1093/toxsci/kfs274] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
104 Lohrke J, Frenzel T, Endrikat J, Alves FC, Grist TM, Law M, Lee JM, Leiner T, Li KC, Nikolaou K, Prince MR, Schild HH, Weinreb JC, Yoshikawa K, Pietsch H. 25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives. Adv Ther 2016;33:1-28. [PMID: 26809251 DOI: 10.1007/s12325-015-0275-4] [Cited by in Crossref: 169] [Cited by in F6Publishing: 131] [Article Influence: 33.8] [Reference Citation Analysis]
105 Dahanayake V, Lyons T, Kerwin B, Rodriguez O, Albanese C, Parasido E, Lee Y, Keuren EV, Li L, Maxey E, Paunesku T, Woloschak G, Stoll SL. Paramagnetic Mn8Fe4-co-Polystyrene Nanobeads as a Potential T1-T2 Multimodal Magnetic Resonance Imaging Contrast Agent with In Vivo Studies. ACS Appl Mater Interfaces 2021;13:39042-54. [PMID: 34375073 DOI: 10.1021/acsami.1c09232] [Reference Citation Analysis]
106 Tsushima Y, Awai K, Shinoda G, Miyoshi H, Chosa M, Sunaya T, Endrikat J. Post-marketing surveillance of gadobutrol for contrast-enhanced magnetic resonance imaging in Japan. Jpn J Radiol 2018;36:676-85. [PMID: 30232584 DOI: 10.1007/s11604-018-0778-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
107 Anbu S, Hoffmann SHL, Carniato F, Kenning L, Price TW, Prior TJ, Botta M, Martins AF, Stasiuk GJ. A Single-Pot Template Reaction Towards a Manganese-Based T1 Contrast Agent. Angew Chem Int Ed Engl 2021;60:10736-44. [PMID: 33624910 DOI: 10.1002/anie.202100885] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
108 Robic C, Port M, Rousseaux O, Louguet S, Fretellier N, Catoen S, Factor C, Le Greneur S, Medina C, Bourrinet P, Raynal I, Idée JM, Corot C. Physicochemical and Pharmacokinetic Profiles of Gadopiclenol: A New Macrocyclic Gadolinium Chelate With High T1 Relaxivity. Invest Radiol 2019;54:475-84. [PMID: 30973459 DOI: 10.1097/RLI.0000000000000563] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 17.0] [Reference Citation Analysis]
109 Sherry AD, Caravan P, Lenkinski RE. Primer on gadolinium chemistry. J Magn Reson Imaging 2009;30:1240-8. [PMID: 19938036 DOI: 10.1002/jmri.21966] [Cited by in Crossref: 255] [Cited by in F6Publishing: 228] [Article Influence: 23.2] [Reference Citation Analysis]
110 Fretellier N, Idée JM, Dencausse A, Karroum O, Guerret S, Poveda N, Jestin G, Factor C, Raynal I, Zamia P, Port M, Corot C. Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study. Invest Radiol 2011;46:292-300. [PMID: 21263333 DOI: 10.1097/RLI.0b013e3182056ccf] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
111 Brücher E, Tircsó G, Baranyai Z, Kovács Z, Sherry AD. Stability and Toxicity of Contrast Agents. In: Merbach A, Helm L, Tóth É, editors. The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging. Chichester: John Wiley & Sons, Ltd; 2013. pp. 157-208. [DOI: 10.1002/9781118503652.ch4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
112 Stojanov D, Aracki-Trenkic A, Benedeto-Stojanov D. Gadolinium deposition within the dentate nucleus and globus pallidus after repeated administrations of gadolinium-based contrast agents-current status. Neuroradiology. 2016;58:433-441. [PMID: 26873830 DOI: 10.1007/s00234-016-1658-1] [Cited by in Crossref: 88] [Cited by in F6Publishing: 71] [Article Influence: 17.6] [Reference Citation Analysis]
113 Taupitz M, Stolzenburg N, Ebert M, Schnorr J, Hauptmann R, Kratz H, Hamm B, Wagner S. Gadolinium-containing magnetic resonance contrast media: investigation on the possible transchelation of Gd³⁺ to the glycosaminoglycan heparin. Contrast Media Mol Imaging 2013;8:108-16. [PMID: 23281283 DOI: 10.1002/cmmi.1500] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
114 Baek AR, Kim H, Park S, Lee GH, Kang HJ, Jung J, Park J, Ryeom H, Kim T, Chang Y. Gadolinium Complex of 1,4,7,10-Tetraazacyclododecane-1,4,7-trisacetic Acid (DO3A)–Ethoxybenzyl (EOB) Conjugate as a New Macrocyclic Hepatobiliary MRI Contrast Agent. J Med Chem 2017;60:4861-8. [DOI: 10.1021/acs.jmedchem.7b00060] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
115 Mayr M, Burkhalter F, Bongartz G. Nephrogenic systemic fibrosis: Clinical spectrum of disease. J Magn Reson Imaging 2009;30:1289-97. [DOI: 10.1002/jmri.21975] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
116 Zhang W, Hui L, Zhang B, Ren L, Zhu J, Wang F, Li S. The Correlation Between Endolymphatic Hydrops and Clinical Features of Meniere Disease. Laryngoscope 2021;131:E144-50. [PMID: 32083730 DOI: 10.1002/lary.28576] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
117 Hequet E, Henoumont C, Muller RN, Laurent S. Fluorinated MRI contrast agents and their versatile applications in the biomedical field. Future Medicinal Chemistry 2019;11:1157-75. [DOI: 10.4155/fmc-2018-0463] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
118 Fretellier N, Idée JM, Guerret S, Hollenbeck C, Hartmann D, González W, Robic C, Port M, Corot C. Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis. Invest Radiol 2011;46:85-93. [PMID: 20938344 DOI: 10.1097/RLI.0b013e3181f54044] [Cited by in Crossref: 44] [Cited by in F6Publishing: 9] [Article Influence: 4.4] [Reference Citation Analysis]
119 Aime S, Caravan P. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging. 2009;30:1259-1267. [PMID: 19938038 DOI: 10.1002/jmri.21969] [Cited by in Crossref: 343] [Cited by in F6Publishing: 308] [Article Influence: 31.2] [Reference Citation Analysis]
120 de Angelis P, Miller RK, Darrah TH, Katzman PJ, Pressman EK, Kent TR, O'brien KO. Elemental content of the placenta: A comparison between two high-risk obstetrical populations, adult women carrying multiples and adolescents carrying singletons. Environmental Research 2017;158:553-65. [DOI: 10.1016/j.envres.2017.07.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
121 Michaely HJ, Aschauer M, Deutschmann H, Bongartz G, Gutberlet M, Woitek R, Ertl-Wagner B, Kucharczyk W, Hammerstingl R, De Cobelli F, Rosenberg M, Balzer T, Endrikat J. Gadobutrol in Renally Impaired Patients: Results of the GRIP Study. Invest Radiol 2017;52:55-60. [PMID: 27529464 DOI: 10.1097/RLI.0000000000000307] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
122 Strzeminska I, Factor C, Robert P, Grindel AL, Comby PO, Szpunar J, Corot C, Lobinski R. Long-Term Evaluation of Gadolinium Retention in Rat Brain After Single Injection of a Clinically Relevant Dose of Gadolinium-Based Contrast Agents. Invest Radiol 2020;55:138-43. [PMID: 31917763 DOI: 10.1097/RLI.0000000000000623] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 10.0] [Reference Citation Analysis]
123 Xie J, Zhang W, Zhu J, Hui L, Li S, Zhang B. Comparison of inner ear MRI enhancement in patients with Meniere's disease after intravenous injection of gadobutrol, gadoterate meglumine, or gadodiamide. Eur J Radiol 2021;139:109682. [PMID: 33813284 DOI: 10.1016/j.ejrad.2021.109682] [Reference Citation Analysis]
124 Jones RA, Votaw JR, Salman K, Sharma P, Lurie C, Kalb B, Martin DR. Magnetic resonance imaging evaluation of renal structure and function related to disease: Technical review of image acquisition, postprocessing, and mathematical modeling steps. J Magn Reson Imaging 2011;33:1270-83. [DOI: 10.1002/jmri.22335] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
125 Ye Z, Wu X, Tan M, Jesberger J, Grisworld M, Lu ZR. Synthesis and evaluation of a polydisulfide with Gd-DOTA monoamide side chains as a biodegradable macromolecular contrast agent for MR blood pool imaging. Contrast Media Mol Imaging 2013;8:220-8. [PMID: 23606425 DOI: 10.1002/cmmi.1520] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
126 Bower DV, Richter JK, von Tengg-kobligk H, Heverhagen JT, Runge VM. Gadolinium-Based MRI Contrast Agents Induce Mitochondrial Toxicity and Cell Death in Human Neurons, and Toxicity Increases With Reduced Kinetic Stability of the Agent: . Investigative Radiology 2019;54:453-63. [DOI: 10.1097/rli.0000000000000567] [Cited by in Crossref: 31] [Cited by in F6Publishing: 4] [Article Influence: 15.5] [Reference Citation Analysis]
127 Endrikat J, Vogtlaender K, Dohanish S, Balzer T, Breuer J. Safety of Gadobutrol: Results From 42 Clinical Phase II to IV Studies and Postmarketing Surveillance After 29 Million Applications. Invest Radiol 2016;51:537-43. [PMID: 26964075 DOI: 10.1097/RLI.0000000000000270] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
128 Bhagavathula N, Dame MK, DaSilva M, Jenkins W, Aslam MN, Perone P, Varani J. Fibroblast response to gadolinium: role for platelet-derived growth factor receptor. Invest Radiol 2010;45:769-77. [PMID: 20714270 DOI: 10.1097/RLI.0b013e3181e943d2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
129 Lancelot E. Revisiting the Pharmacokinetic Profiles of Gadolinium-Based Contrast Agents: Differences in Long-Term Biodistribution and Excretion. Invest Radiol 2016;51:691-700. [DOI: 10.1097/rli.0000000000000280] [Cited by in Crossref: 62] [Cited by in F6Publishing: 18] [Article Influence: 12.4] [Reference Citation Analysis]
130 Rogosnitzky M, Branch S. Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Biometals 2016;29:365-76. [PMID: 27053146 DOI: 10.1007/s10534-016-9931-7] [Cited by in Crossref: 336] [Cited by in F6Publishing: 265] [Article Influence: 67.2] [Reference Citation Analysis]
131 Layne KA, Dargan PI, Archer JRH, Wood DM. Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents. Br J Clin Pharmacol 2018;84:2522-34. [PMID: 30032482 DOI: 10.1111/bcp.13718] [Cited by in Crossref: 60] [Cited by in F6Publishing: 50] [Article Influence: 20.0] [Reference Citation Analysis]
132 Steger-hartmann T, Hofmeister R, Ernst R, Pietsch H, Sieber MA, Walter J. A Review of Preclinical Safety Data for Magnevist (Gadopentetate Dimeglumine) in the Context of Nephrogenic Systemic Fibrosis: . Investigative Radiology 2010;45:520-8. [DOI: 10.1097/rli.0b013e3181e960c9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
133 Park JE, Kim JY, Kim HS, Shim WH. Comparison of Dynamic Contrast-Enhancement Parameters between Gadobutrol and Gadoterate Meglumine in Posttreatment Glioma: A Prospective Intraindividual Study. AJNR Am J Neuroradiol 2020;41:2041-8. [PMID: 33060100 DOI: 10.3174/ajnr.A6792] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
134 Kobayashi M, Levendovszky SR, Hippe DS, Hasegawa M, Murata N, Murata K, Marshall DA, Gonzalez-Cuyar LF, Maravilla KR. Comparison of Human Tissue Gadolinium Retention and Elimination between Gadoteridol and Gadobenate. Radiology 2021;:204320. [PMID: 34128720 DOI: 10.1148/radiol.2021204320] [Reference Citation Analysis]